Videos

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

Alyson McGregor, MD, of Brown University explains what pharmacists should understand about the impact of sex and gender on medicine within their practice.

Drs Bradley J. Monk, Sarah Hayward, and Jennifer MacDonald comment on monitoring and managing adverse events with PARP inhibitor therapy in patients with ovarian cancer in the frontline maintenance setting.

Bradley J. Monk, MD, FACS, FACOG, and Jennifer MacDonald, PharmD, BCOP, share insight on improving outcomes and optimizing therapy with PARP inhibitors in the frontline maintenance setting for ovarian cancer.

Dr Sarah Hayward leads the discussion on optimal approaches to influence patient compliance to PARP inhibitor therapy for frontline maintenance in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, leads the discussion on the efficacy of currently approved PARP inhibitors used in the first-line maintenance setting for ovarian cancer and how pharmacists can help patients overcome access barriers.

Sarah Hayward, PharmD, BCOP, leads the discussion on common toxicities and when to create dose adjustments for first-line maintenance therapy in patients with ovarian cancer.

Experts in gynecologic oncology provide insight on educating patients with ovarian cancer on the duration of maintenance therapy.

Recommendations for classifying and treating patients with progressive Waldenstrom macroglobulinemia.

The top considerations of hematologists and oncologists when selecting first-line treatment for patients with Waldenstrom macroglobulinemia.

Drs Jennifer MacDonald, Bradley J. Monk, and Sarah Hayward review current FDA-approved PARP inhibitors for first-line maintenance therapy for patients with ovarian cancer.

Alyson McGregor, MD, of Brown University explains what pharmacists can do to advance issues arising around the impact of sex and gender on medicine.

A panel of doctors explains whether or not someone can get a different COVID-19 booster from their original vaccinations and how they compare.

Experts discuss who is eligible for COVID-19 booster shots and the misinformation around COVID-19 vaccinations.

Abby Sauer, a registered dietitian specializing in adult nutrition at Abbott, discusses how the unique nutritional needs of women evolve with age and some tips pharmacists can provide to women 30 years of age and older in the pharmacy.

Rebecca Sleeper, PharmD, FCCP, FASCP, BCPS, of the Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, discusses how a lack of sex and gender specific patient care education can impact a pharmacist’s work with their patients.

Alyson McGregor, MD, of Brown University discusses the focus of her research into sex and gender in emergency medicine.

Angela Rasmussen, PhD, and Donald Alcendor, PhD have a conversation on the recent expansion of COVID-19 booster shot usage in eligible populations.

Key opinion leaders debate on the necessity of COVID-19 booster shots.

Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.

The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses her hopes for the future of SHC’s diabetes DRIVE program and its adoption within health systems.

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, provides some closing thoughts on sex and gender in health care.

Burnout in pharmacy can be managed with the proper planning and the right techniques for your preference.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses the problems with approaching public health issues, such as mental health and substance use disorders, with an industrialized approach to problem solving.

Sarah Temkin, MD, of the Office of Research on Women’s Health at the National Institutes of Health, discusses some key points for pharmacists on the impact of biological and sociological variables on treatment outcomes.

Tom Hanzel, PharmD, MBA, discussed how vaccine mandates impact staffing shortages in long-term care facilities.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses whether the adoption and acknowledgement of psychedelic medicine in health care systems looks likely for the future.

Tom Hanzel, PharmD, MBA, of Parata Systems, discussed challenges in pharmacy workflow and how automation could offer solutions.